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1. Introduction 
Several neurodegenerative diseases are associated with a build up of misfolded or abnormal 
proteins and the formation of distinct aggregates, resulting in a putative pathological 
protein load on the nervous system (Chiti & Dobson, 2006). This aberrant accumulation of 
amyloid or amyloid-like aggregates occurs in Parkinson’s (PD), Alzheimer’s (AD), and 
Huntington’s (HD) diseases, amyotrophic lateral sclerosis, and frontotemporal dementia, 
among others. A broad array of cellular defence mechanisms operate to counteract this 
effect, including antioxidant proteins, the stress-inducible response and, in particular, 
molecular chaperones (Morimoto, 2008; Voisine et al., 2010). Molecular chaperones are 
responsible for maintaining normal protein homeostasis within the cell by assisting protein 
folding, inhibiting protein aggregation, and modulating protein degradation pathways 
(Hartl & Hayer-Hartl, 2009). Currently, there is substantial evidence supporting the 
involvement of these protein aggregational processes and a role of molecular chaperones, 
and especially of Hsp70, in PD pathogenesis (Bandopadhyay & de Belleroche, 2010; 
Broadley & Hartl, 2009; Witt, 2009). Firstly, extensive colocalization of Hsp70 with α-
synuclein (αSyn), the major component of Lewy bodies (LBs) (Spillantini et al., 1998), within 
the intraneuronal inclusions in PD brains has been demonstrated (Auluck et al., 2002; 
McLean et al., 2002). Secondly, patients with PD show highly perturbed expression of 
different members of the Hsp70 family in the substantia nigra pars compacta (SN) of the brain, 
which is precisely the target of neurodegeneration (Grunblatt et al., 2001; Hauser et al., 
2005). Finally, there is a considerable amount of data derived from studies performed in 
vitro, in cell culture and with animal models of PD (Arawaka et al., 2010; Witt, 2009), that 
support the protective effects of Hsp70 against αSyn aggregation and toxicity, considered to 
be central in the aetiology of  the disease. 
The discovery within the last few years of three different missense mutations (A30P, E46K 
and A53T) in the αSyn gene as causative of early onset PD unambiguously linked this 
protein to disease onset and progression (Kruger et al., 1998; Polymeropoulos et al., 1997; 
Zarranz et al., 2004). Additionally, a locus triplication causing an increased dosage of the 
wild-type฀ (Wt)฀αSyn gene has been found to potentiate neurodegeneration (Singleton et al., 
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2003). Finally, as mentioned above, αSyn is the major component of intracellular protein-
rich aggregates found in the brain of post-mortem patients of PD, the LBs and Lewy neurites 
(LNs). The appealing hypothesis for LBs formation is that αSyn monomers combine to form 
oligomers (or protofibrils), which coalesce into fibrils and then co-aggregate with other 
proteins into (intracellular) inclusions (Conway et al., 1998; Wood et al., 1999). While the 
monomers and oligomers of αSyn are soluble, the fibrils and LBs are insoluble in the 
neuronal cytoplasm. Some controversy arises, however, from the roles of the various 
physical forms or species of αSyn in PD pathogenesis. LBs have been proposed to be both 
neurotoxic (El-Agnaf et al., 1998), and protective (Mouradian, 2002; Rochet et al., 2000). 
Other hypotheses state that the pre-fibrillar intermediates, composed of αSyn oligomers, are 
the main toxic species towards dopaminergic neurons (Conway et al., 2000; Volles & 
Lansbury, 2003). Lansbury and co-workers have shown that αSyn oligomers can form 
annular, elliptical, or circular amyloid pores in cell membranes (Lashuel et al., 2002a; Volles 
& Lansbury, 2003), and cell culture studies have demonstrated that αSyn oligomers reduce 
cell viability, disrupt lysosomes and induce Golgi fragmentation (Gosavi et al., 2002), as well 
as toxicity in animal models (Karpinar et al., 2009). In line with these findings, the more 
neurotoxic A30P and A53T mutants of αSyn share an increased tendency to form soluble 
oligomeric intermediates, whereas the E46K and A53T mutants fibrillate faster than the 
wild-type protein (Conway et al., 2000; Choi et al., 2004). 
The heat-shock-protein 70 (Hsp70) family of chaperones (Mayer & Bukau, 2005; Young, 
2010) is well conserved from bacteria to higher eukaryotes (where it is found within 
different organelles), having critical roles in a range of cellular processes such as promoting 
the folding of newly synthesized proteins and assisting the rescue of misfolded aggregated 
proteins. Hsp70 is highly relevant in the context of protein conformational diseases given 
that stress-induced cytosolic Hsp70 can prevent protein aggregation and enables the cell to 
avoid the accumulation of potentially toxic aggregates (Hartl, 1996).  
The structures of several Hsp70 homologues are similar and consist of an actin-like ATPase 
domain (nucleotide-binding domain, NBD) and a and a C-terminal substrate-binding domain 
(SBD), which are connected by a short linker region (Mayer & Bukau, 2005). The substrate 
binding pocket recognizes and binds to unstructured or partially folded stretches within 
polypeptides (Bukau & Horwich, 1998), with the current view that Hsp70s could prevent 
misfolding by binding to certain patterns in the polypeptide chain of the substrate that are 
highly enriched in hydrophobic residues (Maeda et al., 2007; Rudiger et al., 1997). Even though 
most of our current understanding of the Hsp70 molecular mechanism has largely derived 
from studies performed with the bacterial orthologue (DnaK), the outlines of the mechanism 
appear conserved (Hartl & Hayer-Hartl, 2002; Young, 2010). The ATPase cycle of Hsp70 
involves alternation between an ATP-bound state which has low affinity and fast exchange 
rates for peptide substrates (‘open’ state), and an ADP-bound state with high affinity and low 
exchange rates for substrates (‘closed’ state) (Mayer & Bukau, 2005). This alternation is 
achieved by a bidirectional structural communication between the NBD and the SBD domains, 
driven by a complex allosteric mechanism (Mayer & Bukau, 2005; Young, 2010). 
The ATPase cycle is typically modulated by several co-chaperones, most notably the ‘J-
domain’ protein Hsp40/DNAJB1 (or DnaJ, the bacterial orthologue), resulting in increase of 
the ATPase activity  (Bukau & Horwich, 1998; Mayer & Bukau, 2005; Minami et al., 1996), 
and the BAG family of proteins which function as nucleotide-exchange factors (NEFs) and 
promote the ADP release from the the Hsp70 NBD (Takayama et al., 1999; Young, 2010). In 
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addition to acting as enhancer of the basal ATPase rate of Hsp70, the Hsp40 family of co-
chaperones has a key role in the canonical model of the Hsp70 machinery mechanism, given 
the ability of some of them to also recognize and bind to unfolded client proteins and 
‘deliver’ them to Hsp70 (Kampinga & Craig, 2010). Other important co-chaperones are Hop, 
which binds to the C-termini of Hsp70 and Hsp90 and assists substrate transfer between the 
two chaperones (Scheufler et al., 2000), and Hip (ST13) which has been shown to specifically 
bind to and stabilize, the ADP-bound state of Hsp70 (Hohfeld et al., 1995; Prapapanich et al., 
1996), and has been suggested to increase the half-life of Hsp70-substrate complexes 
(Hohfeld et al., 1995). Finally, CHIP (Ballinger et al., 1999) acts as an E3-ubiquitin ligase that 
ubiquitinates HSPA8/Hsc70/Hsp73 (i.e. the constitutive cytosolic Hsp70) substrates, 
promoting their degradation by the proteasome (Hohfeld et al., 2001).  
2. Links between Hsp70 and the pathogenesis of PD 
PD is currently thought to involve different pathogenic mechanisms that eventually lead to 
neurodegeneration, as discussed elsewhere in this book series.. There is substantial evidence 
supporting a prominent role in PD-related cell death of αSyn toxic oligomers. One 
hypothesis postulates that certain αSyn species can affect the homeostasis of cell membranes 
(Gupta et al., 2008; Lashuel et al., 2002b; Volles & Lansbury, 2002), and produce ER and 
oxidative stress, UPS and mitochondrial dysfunction (Gupta et al., 2008; Jellinger, 2010), as 
well as neuroinflammation  (Jellinger, 2010; Roodveldt et al., 2008) processes, all of which 
have been linked, to a lower or larger extent, to the amyloid-like aggregation of αSyn. As 
will be described below, the Hsp70 system has been found to be a key player in 
counteracting most of these processes, not only by physically interacting with αSyn, but also 
by promoting aggregation clearance (Figure 1). 
 
 
Fig. 1. Links between Hsp70 and the multiple αSyn-mediated processes in PD pathogenesis. 
CMA: chaperone-mediated autophagy; UPS: ubiquitin-proteasome system; LB: Lewy 
bodies; LN: Lewy neurites. Discontinuous lines depict the possible ‘sequestration’ of certain 
chaperones by αSyn aggregating species. 
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2.1 Hsp70 in modulation of αSyn aggregation and cytotoxicity 
Heat-shock proteins (HSPs) prevent and reverse the misfolding and aggregation of proteins, 
and the Hsp70 family in particular is known to play important roles in protecting neurons 
from protein aggregation-derived stress (Lu et al., 2010). Therefore, it might not seem 
surprising that Hsp70 has been found to be linked to several neurodegenerative processes 
and ‘conformational’ disorders, including PD (Witt, 2009). Notably, Hsp70 has been shown 
to colocalize with aggregated฀αSyn within LBs in brains from PD patients (Auluck et al., 
2002), strongly suggesting a role for this chaperone in managing αSyn aggregates in the 
context of PD (Figure 1). It is then that a substantial portion of the research in the field has 
focused on the effects of this major cytosolic chaperone on αSyn aggregation and 
cytotoxicity. Following the discovery that Hsp70 can abrogate the neurotoxicity of abnormal 
polyglutamine proteins (Warrick et al., 1999), it was shown that Hsp70 can also prevent 
dopaminergic neuronal loss associated with αSyn in a Drosophila PD model (Auluck et al., 
2002). Numerous studies that followed have reported that over-expression of Hsp70 is able 
to reduce αSyn aggregation and/or toxicity in various cellular models (Danzer et al., 2011; 
Klucken et al., 2004b; McLean et al., 2004; Opazo et al., 2008; Outeiro et al., 2008; Zhou et al., 
2004). In particular, McLean and co-workers (Outeiro et al., 2008) have found that Hsp70 
rescues αSyn-linked toxicity by promoting the cellular clearance of αSyn oligomers, rather 
than monomers. Another study (Opazo et al., 2008) found that Hsp70 manages αSyn 
intracellular aggregation by increasing the clearing of aggregates primarily through the 
aggresome, and the subsequent removal of small aggregates and aggresomes from the 
cytosol. An interesting study by McLean and colleagues (Danzer et al., 2011) has recently 
shown that Hsp70 can also inhibit the formation of extracellular αSyn oligomers and rescue 
the cytotoxicity produced by such secreted oligomers, in a cellular model. Moreover, their 
data also indicates that Hsp70 is released to the extracellular medium together with secreted 
αSyn, adding to the accumulating evidence that Hsp70 can be released from cells by an 
active mechanism, with functionally relevant consequences. 
Intriguingly, while it was found that over-expression of Hsp70 can prevent αSyn 
aggregation in a Wt αSyn transgenic mouse model (Klucken et al., 2004b), a recent work 
based on A53T-αSyn transgenic mice has failed to observe this effect (Shimshek et al., 2010), 
seeding some controversy. Could these findings reflect a difference in the nature of the 
aggregates generated by Wt and mutant αSyn, and therefore a differential ability of Hsp70 
to cope with those aggregates? Even though there is compelling evidence demonstrating the 
important role of Hsp70 under physiological and pathological scenarios in modulating fibril 
formation based on in vivo and cellular models, the molecular mechanism underlying such 
anti-aggregation properties in the context of PD, is still not fully understood. 
Unlike the many research works performed with PD cellular and animal models that have 
contributed to our understanding on Hsp70 function under physiological or pathological 
conditions, only a handful of studies have focused on the molecular mechanism and 
interactions that underlie the modulation of ǂSyn aggregation exerted by Hsp70. An in-cell 
fluorescence resonance energy transfer (FRET) study indicated that Hsp70 alters the 
conformation of αSyn, inducing it to adopt a more ‘open’ conformation, without affecting 
the αSyn-αSyn intermolecular interactions (Klucken et al., 2006). Similarly to what had been 
found in vitro for Hsp70 and the HD-related huntingtin protein (Muchowski et al., 2000; 
Wacker et al., 2004), several studies with αSyn have shown that Hsp70 is able to suppress 
αSyn fibril assembly. In this case, a variety of in vitro studies have shown that this efficient 
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inhibition of amyloid assembly can occur in the absence of collaborating co-chaperones and 
in an ATP-independent manner (Ahmad, 2010; Dedmon et al., 2005; Huang et al., 2006; Luk 
et al., 2008; Roodveldt et al., 2009), while promoting formation of small oligomeric species of 
moderate toxicity (Roodveldt et al., 2009). However, our recent study demonstrates that, 
even though Hsp70 is indeed able to control αSyn fibrillation and its associated toxicity in 
an ATP-independent manner, it does so more efficiently in the presence of ATP (Roodveldt 
et al., 2009), consistent with the results obtained with a cellular model (Klucken et al., 2004a). 
Nevertheless, this ATP-dependent activity was found to require Hip co-chaperone activity, 
and not Hsp40 as observed in the case of mutant huntingtin protein (Lotz et al., 2010), 
suggesting that Hsp70 can function through different molecular mechanisms, depending on 
the nature of the aggregating client protein.  
Interestingly, our study also showed that Hsp70 in the presence of ATP is prone to co-
aggregate with aggregating αSyn, presumably caused by the formation of a highly insoluble 
(ADP)Hsp70/αSyn complex. Surprisingly, this co-aggregation can be prevented by the 
addition of the co-chaperone Hip (St13), which had been found to be under-expressed in 
serum of PD patients since the early stages of the disease (Scherzer et al., 2007). The 
relevance of Hip in assisting the suppression of αSyn aggregation in an Hsp70-dependent 
manner was further supported by a study we performed in a C. elegans model of PD 
(Roodveldt et al., 2009), in which knock-down of Hip produced a much stronger PD 
phenotype than knock-down of Hsp70, shown by higher levels of αSyn aggregation in the 
former condition. This finding indicates that Hip co-chaperone could be important not only 
in modulating the chaperone’s molecular mechanism, but also in guarding the functionality 
and availability of Hsp70 under certain conditions. 
One relevant question relates to the nature of the species along the aggregation pathway of 
αSyn that are specifically recognized and targeted by Hsp70. Initially, Hsp70 was reported 
to bind to αSyn filaments in vitro (Lindersson et al., 2004). However, it is currently 
understood that Hsp70 does not disaggregate or alter the structural properties of mature 
αSyn fibrils (Dedmon et al., 2005), but rather inhibits fibril formation via interactions with 
soluble pre-fibrillar forms of αSyn. A few studies performed with cell extracts (Zhou et al., 
2004) and with live cells (Klucken et al., 2006), in addition to experiments with purified 
proteins (Dedmon et al., 2005; Huang et al., 2006; Roodveldt et al., 2009), demonstrate the 
existence of molecular interactions between Hsp70 and αSyn oligomeric species. Even 
though previous attempts to isolate such complexes by co-immunoprecipitation or pull-
down experiments had failed (Luk et al., 2008),  we have been able to probe the formation of 
a complex between Hsp70 and αSyn oligomeric species by FRET (Roodveldt et al., 2009), 
suggesting that these interactions are transient (Luk et al., 2008; Roodveldt et al., 2009), 
besides being highly dynamic (Luk et al., 2008; Roodveldt et al., 2009). 
In addition, we have recently shown by FRET and nuclear magnetic resonance (NMR) 
analyses that, contrary to what was previously thought, Hsp70 can also interact with αSyn 
monomeric species (Roodveldt et al., 2009) with an affinity constant lying within the low 
micromolar range. Moreover, the fluorimetric study revealed the existence of diverse 
Hsp70/αSyn complexes that are formed depending on the nucleotide state of the chaperone, 
either nucleotide-free, or ATP- or ADP-bound, that are sampled along the ATPase cycle. 
Based on these structural studies, we have proposed that a particularly ‘compact’ 
Hsp70/αSyn complex in the ADP-state of Hsp70 that arises during the aggregation process 
of αSyn, leads to Hsp70 being entrapped or sequestered by the oligomers. However, we 
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propose that this compact complex can be stabilized by the Hip co-chaperone and therefore 
the co-aggregation of the chaperone, and ultimately the formation of αSyn fibrils, can be 
prevented (Roodveldt et al., 2009). In other words, our findings indicated that a decreased 
expression of Hip could facilitate depletion of Hsp70 by amyloidogenic polypeptides, 
impairing chaperone proteostasis. Interestingly, another case of chaperone-
inhibition/depletion by αSyn oligomers, but not by unstructured monomers, was recently 
reported for the Hsp70/Hsp40 system (Hinault et al., 2010). In this case, the authors found 
that the inhibition of the chaperone system was predominantly caused by the sequestration 
or incapacitation, by off-pathway αSyn oligomers, of the J-domain (Hsp40) co-chaperone 
(Hinault et al., 2010). 
What is the region on the αSyn molecule thought to be recognized and bound by Hsp70? 
One study mapped this region as the broad segment between residues 21 and 110 (Luk et 
al., 2008). Based on a predictive algorithm for Hsp70-binding regions (Rudiger et al., 1997) 
and FRET analyses to probe Hsp70-ǂSyn interactions (Roodveldt et al., 2009), our results 
indicate that Hsp70 can bind to the N-terminus and the central NAC region of the protein. 
The first binding region is involved in functional lipid interactions, while the second one 
comprises the stretch of hydrophobic residues that readily forms fibrils in vitro and is 
generally assumed to be involved in initiating the fibrillation process (Giasson et al., 2001). 
In addition, our results suggest that Hsp70 also interacts with the negatively charged C-
terminus of the αSyn molecule, especially in the nucleotide-free state. Taken together, the 
studies carried out thus far demonstrate that Hsp70 modulates αSyn aggregation by 
interacting with the protein at different stages of aggregation, by recognizing essentially two 
or three regions in the αSyn molecule, and forming different transient complexes with the 
substrate. The strong binding versatility displayed by Hsp70 with aggregating αSyn might 
be possible thanks to the large structural flexibility conferred by the lid subdomain within 
the SBD, that has been recently described by Mayer and colleagues (Schlecht et al., 2011). 
2.2 Cooperation of Hsp70 with the ubiquitin-proteasome system (UPS) 
2.2.1 Involvement of the ubiquitin-proteasome system in PD 
The ubiquitin-proteasome system (UPS) is responsible for the degradation of vital 
regulatory proteins that control almost every cellular function (Hershko & Ciechanover, 
1998). The UPS system is composed of three classes of ubiquitinating enzymes (E1, E2 and 
E3) that activate, transfer and attach the small protein ubiquitin to the Lys residues of 
proteins that are targeted for degradation. Conjugation of at least four ubiquitin moieties 
acts as the degradation signal in a process that is initiated by the recognition of the ubiquitin 
linkage by the proteasome, which first catalyzes the unfolding and then the proteolysis of 
the targeted protein (Hershko & Ciechanover, 1998). 
Impairment in the UPS has been linked to many neurodegenerative disorders and indeed to 
contribute to disease progression in PD (Ciechanover & Brundin, 2003; Cook & Petrucelli, 
2009; McNaught et al., 2001). The involvement of UPS in PD arouse major interest with the 
identification of mutations in the E3 ubiquitin ligase parkin protein as a cause of autosomal 
recessive PD (Kitada et al., 1998). Both the loss of E3 activity and the possibility of 
incomplete or aberrant ubiquitination are proposed as causes of parkin-related PD (Giasson 
& Lee, 2003). A second member of the UPS involved in PD is the ubiquitin carboxy-terminal 
hydrolase-L1 (UCH-L1), and mutations in the uchl-1 gene cause dysfunction of this enzyme 
and lead to accumulation of toxic products (Leroy et al., 1998). 
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Beyond the clear genetic association between the UPS and PD, several studies have 
demonstrated a reduced proteolytic activity in the SN of PD patients when compared with 
aged-matched controls (McNaught et al., 2003; McNaught & Jenner, 2001; McNaught & 
Olanow, 2006). In culture of rat primary neurons, treatment with proteasomal inhibitors has 
shown to lead to the formation of αSyn- and ubiquitin- positive proteinaceous inclusions, 
analogous to LBs found in PD patients (McNaught et al., 2002a; Rideout et al., 2005). 
Moreover, systemic administration of proteasomal inhibitors in rats produced a behavioural 
and pathological phenotype strongly reminiscent of PD (McNaught et al., 2004), although 
recently some controversy arose in this matter (Manning-Bog et al., 2006). Further support to 
the active role played by proteasomal impairment in PD progression originated from 
studies with pesticides, such as rotenone and paraquat (Cook & Petrucelli, 2009). Mice 
treated with such environmental toxins display a strong reduction in proteolytic activity 
that is dependent on the presence of αSyn (Fornai et al., 2005). All together, these data 
undoubtedly link αSyn aggregation with impairment of the UPS in PD progression. 
In relation to protein misfolding and aggregation, it has been proposed that failure of the 
UPS to adequately remove misfolded or abnormal proteins may underlie demise of nigral 
cells in sporadic PD (McNaught et al., 2001). Furthermore, deficits in the 26/20S proteasome 
pathways are accompanied by protein accumulation and aggregation, which may also cause 
neurodegeneration (Chung et al., 2001), in line with recent findings that general intracellular 
aggregation of proteins into aggresomes can can inhibit the UPS (Bence et al., 2001). 
Moreover, chaperones of the heat-shock families, including HSP27, 40, 70, 60, 90, and 110, as 
well as components of the UPS, such as ubiquitin, UCH-L1 and parkin, are found in LBs 
extracted from PD patients post mortem (Shults, 2006). These combined pieces of evidence 
have attracted much attention lately as they imply that LBs could originate from ubiquitin-
rich aggresomes that the proteasomal components may not be able to process (McNaught et 
al., 2002b). One plausible mechanism would involve αSyn adopting abnormal protein 
conformations and overwhelming the cellular protein degradation systems (Wong & 
Cuervo, 2010), whereas deficits in the UPS machinery would challenge the cell’s ability to 
detect and degrade misfolded proteins that can result in the formation of toxic early 
aggregates (McNaught et al., 2002b). The common outcome of this failure at different levels 
is thus expected to be a cellular build-up of unwanted toxic species that should have been 
cleared in otherwise healthy conditions. Minimal defects in the crucial protein turnover 
machinery may suffice to cause a slow demise of dopaminergic neurons, which may explain 
the relentless, progressive nature of the disease (Vila & Przedborski, 2003). 
Alpha-synuclein extracted from LBs in PD brains has been found to be mono- and di-
ubiquitinated (Hasegawa et al., 2002), while soluble αSyn is mono-ubiquitinated by SIAH-1 
and -2, but not by parkin (Liani et al., 2004; Rott et al., 2008). Instead, a modified, O-
glycosylated, version of αSyn is a substrate for parkin-induced ubiquitination (Shimura et 
al., 2001), and it was shown that  interaction of parkin with αSyn is mediated by synphilin-1 
(Chung et al., 2001)
 
as well as by the protein 14-3-3-η (Sato et al., 2006). Importantly, parkin 
has been shown to be able to rescue primary neurons from the toxic effects of αSyn 
(Petrucelli et al., 2002), suggesting that the two proteins share a common pathway that may 
determine the fate of dopaminergic neurons in PD. In addition, UCH-L1 may be involved in 
regulating the cytoplasmic abundance of αSyn, as it displays unexpected ubiquitin ligase 
activity that is also able to polyubiquitinate mono- and diubiquitinated αSyn (Liu et al., 
2002). Since attachment of at least four ubiquitin molecules is known to be required for 
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protein degradation via the UPS (Hershko & Ciechanover, 1998), it is likely that mono-, di-, 
and aberrant poly-ubiquitinated αSyn could have a pathogenic impact (Rott et al., 2008; Sun 
& Chen, 2004). 
2.2.2 Role of the C-terminus Hsp70-interacting protein (CHIP) in PD 
Hsp70 and Hsp90 family members as well as small HSPs all take part in the degradation of 
protein substrate and are able to cooperate with the UPS towards this goal (Patterson & 
Hohfeld, 2006). Notably, protein homeostasis thus appears to be tightly controlled by 
interplay between the protein folding and protein degradation systems. Hsp70 takes part in 
the degradation of immature and aberrant forms of certain proteins, particularly ER-bound 
membrane proteins (Taxis et al., 2003), but also some cytosolic and nuclear proteins 
(Bercovich et al., 1997). For example, Hsp70 assists in the folding of the aggregation prone 
cystic fibrosis transmembrane conductance regulator (CFTR); however, Hsp70 is also able to 
present CFTR to the UPS and thus to control precisely the abundance of this protein, which 
is known to accumulate in aggresome and to cause cystic fibrosis (Zhang et al., 2001). 
Indeed, Hsp70 is actively recruited to aggresome and it has been proposed that this 
chaperone can reduce aggresome formation by stimulating proteasomal degradation of 
misfolded proteins (Dul et al., 2001; Garcia-Mata et al., 1999). The proposed mechanism for 
chaperone-UPS cooperation is that both systems compete for the same misfolded and 
aggregation-prone substrate proteins, and that the efficiency of chaperones in maintaining 
these proteins in solution increments the probability of the UPS to degrade aberrant 
polypeptides. Conversely, failure of chaperones to keep misfolded proteins in a soluble state 
gives rise to aggregates that are not efficiently degraded by the UPS and, moreover, may 
inhibit UPS activity towards other protein targets, altering protein homeostasis (Figure 1). 
Insights into the mechanism that enables the cooperation of protein chaperones with the 
UPS have been obtained from the identification and functional characterization of the C-
terminal Hsp70 interacting protein (CHIP) co-chaperone (Ballinger et al., 1999; Hohfeld et 
al., 2001; McDonough & Patterson, 2003). CHIP contains three tetratricopeptide repeat (TPR) 
domains that recognize and bind to the EEVD motif in both Hsp70 and Hsp90 (Ballinger et 
al., 1999). CHIP-complexed Hsp70 displays reduced ATP hydrolysis in vitro, suggesting that 
the co-chaperone diminishes the on-rate of binding and release cycles in Hsp70 (Ballinger et 
al., 1999). In its C-terminus, CHIP possesses a ubiquitin ligase domain (U box) that is 
capable of targeting proteins to degradation, in a homologous manner to RING finger 
domains found in E3 ubiquitin ligase enzymes (Connell et al., 2001; Meacham et al., 2001). 
CHIP has been shown to efficiently act as E3 ligase for several Hsp70 and Hsp90 substrates, 
such as the glucocorticoid receptor and Erb2 (Dickey et al., 2007; McDonough & Patterson, 
2003; Murata et al., 2001). Proteins ubiquitinated by CHIP are efficiently targeted to the 
proteasome and subsequently degraded. Notably, the UbcH4/UbcH5 proteins are E2-
conjugating enzymes (Demand et al., 2001) that are stress-activated, suggesting that upon 
stress CHIP furnishes the cell with chaperone-dependent ubiquitin ligases capable of 
ubiquitinating misfolded and aggregation-prone substrates. 
The ubiquitinating activity of CHIP is regulated by two co-chaperones, BAG-1, which is an 
enhancer, and the Hsp70 binding protein 1 (HspBP1), which acts as a repressor. BAG-1 
associates with the ATPase domain of Hsp70 and, in addition, possesses a ubiquitin-like 
domain that is efficiently recognized and bound by the proteasome (Luders et al., 2000). 
Thus, BAG-1 provides the proteasome with the capability to recruit Hsp70 and consequently 
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degrade its cargo clients. A ternary complex involving BAG-1, Hsp70 and CHIP has been 
isolated, and BAG-1 is capable of stimulating CHIP mediated degradation of some proteins 
(Alberti et al., 2002). The co-chaperone HspBP1, in turn, competes with BAG-1 for binding to 
the ATPase domain of Hsp70 (Alberti et al., 2004). Notably, when in complex with HspBP1-
bound Hsp70, CHIP shows a much reduced ubiquitin ligase activity and chaperone 
substrates are not longer ubiquitinated and targeted to the UPS (Alberti et al., 2004). 
In the context of neurodegeneration, CHIP has been shown to intervene in the degradation 
of misfolded aggregation-prone proteins associated with AD, PD and HD, as well as with 
spinocerebellar ataxia and spinal bulbar muscle atrophy (Adachi et al., 2007; Al-Ramahi et 
al., 2006; Hatakeyama et al., 2004; Shin et al., 2005; Urushitani et al., 2004). Indeed, CHIP 
appears to play an active role in modulating αSyn aggregation and degradation (Kalia et al., 
2011; Shin et al., 2005; Tetzlaff et al., 2008). It was shown that CHIP interacts with both 
soluble and aggregated αSyn, and its over-expression reduces αSyn abundance and 
aggregation (Shin et al., 2005). Interestingly, CHIP induces αSyn clearance via two 
alternative pathways, one involving Hsp70 and proteasomal degradation, and another 
Hsp70-independent route that targets αSyn to lysosomes (Shin et al., 2005). A fluorescence-
complementation assay demonstrated that CHIP reduced significantly the abundance of 
αSyn toxic oligomers in cell culture, suggesting that this aberrant species is preferentially 
recognized by the co-chaperone (Tetzlaff et al., 2008). More recently, it was discovered that 
CHIP is an E3 ubiquitin ligase of αSyn since it efficiently conjugates ubiquitin moieties to 
this protein (Kalia et al., 2011). CHIP-catalyzed ubiquitinated forms of αSyn include mono- 
and poly-ubiquitinated species, and the activity of CHIP depends on the presence of Hsp70 
and the co-chaperone BAG5. Contrary to the enhancer activity reported for BAG1, BAG5 
reduces the ability of CHIP to ubiquitinate αSyn in and Hsp70-dependent manner (Kalia et 
al., 2011). 
Additional pathogenic mechanisms in PD that involve the activity of CHIP relate to the 
ubiquitin ligase activity of parkin and the kinase activity of the leucine-rich repeat kinase-2 
(LRRK2). It has been found that CHIP, Hsp70 and parkin form a ternary complex that 
promotes ubiquitination and degradation of the Pael receptor, a protein localized in the ER 
and whose accumulation has been linked to dopaminergic neuronal death (Imai et al., 2002), 
and CHIP has been proposed to enhance the activity of parkin, even in the absence of Hsp70 
(Imai et al., 2002). Concerning LRRK2, CHIP regulates the ubiquitination, degradation, and 
toxicity mediated by pathogenic mutations of this kinase (Ko et al., 2009). Moreover, it has 
been shown that CHIP binds to LRRK2 via its TPR motifs and formation of this complex is 
protective in cell culture models, while in the presence of mutant LRKK2, knock-down of 
CHIP leads to cell death (Ko et al., 2009). 
2.3 Hsp70 in chaperone-mediated autophagy (CMA) 
Macroautophay and chaperone-mediated autophagy (CMA) are the two main lysosomal 
proteolytic systems in mammalian cells for the degradation of intracellular proteins (Xilouri 
& Stefanis, 2011). CMA is the process of degradation of intracellular components by 
lysosomes which selectively degrades cytotolic proteins containing a KFERQ-like motif 
(Koga & Cuervo, 2010). This process is known to involve binding of a complex of 
constitutive cytosolic Hsp70 (Hsc70) and co-chaperones (including Hsp40, Hip, Hsp90 and 
BAG1) to substrate proteins, and their subsequent targeting to lysosomes via the lysosomal 
surface receptor LAMP-2A (Xilouri & Stefanis, 2011). The substrate protein is subsequently 
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degraded after unfolding and translocation into the lysosomal lumen, in a process involving 
lysosomal Hsc70 (Figure 1). It has been estimated that about 30% of cytosolic proteins could 
be subjected to degradation via CMA (Dice, 2007), and furthermore, this pathway  may be a 
major route by which αSyn is degraded in neurons (Witt, 2009). Even though it is currently 
accepted that dysregulation of autophagy plays a role in neurodegeneration 
(Bandyopadhyay & Cuervo, 2007; Nixon, 2006; Rubinsztein, 2006; Xilouri & Stefanis, 2011), 
including the PD neurodegenerative process (Martinez-Vicente et al., 2008; Yang et al., 
2009), the mechanism by which CMA modulates neuronal survival or death, is still unclear. 
Given that pathologic accumulation of αSyn is a hallmark of PD, several recent studies have 
addressed the possible link between αSyn degradation, CMA dysfunction and the 
neurodegenerative process. Indeed, αSyn, which contains a pentapeptide sequence 
(95VKKDQ99) consistent with Hsc70 binding (Dice, 1990), has been shown to be degraded via 
CMA using isolated lysosomal preparations (Cuervo et al., 2004) and neuronal cells 
(Alvarez-Erviti et al., 2010; Martinez-Vicente et al.; Vogiatzi et al., 2008). On the contrary, the 
A30P and A53T αSyn variants were observed to bind strongly to LAMP-2A receptors but 
were not internalized, thus inhibiting the CMA degradation of other substrates (Cuervo et 
al., 2004). This CMA dysfunction was later shown to mediate αSyn toxicity in cellular 
models (Xilouri et al., 2009). Moreover, a recent study using both αSyn transgenic- and 
paraquat- PD mouse models (Mak et al., 2010), showed that αSyn can be degraded in the 
lysosome through CMA, in vivo. The study also revealed an up-regulation of LAMP-2A and 
lysosomal Hsc70 and an increase in Hsc70-αSyn interactions in brain lysosomes, relative to 
controls. On the other hand, a recent work work revealed a significant reduction of both 
LAMP-2A and Hsc70 levels in the SN and amygdala of PD brains, relative to age-matched 
Alzheimer’s disease (AD) and healthy, brain controls (Alvarez-Erviti et al., 2010). Even 
though their results might initially appear contradictory, these findings support a key role 
for Hsc70 and the CMA system in maintaining intracellular general proteostasis, especially 
within the αSyn-overload scenario that is typically associated to PD and other α-
synucleinopathies. 
2.4 Emerging links between the Hsp70 system and neurodegeneration in PD 
2.4.1 The CSPα-Hsc70-SGT complex and neurodegeneration in PD 
Cysteine-string protein α (CSPα) is an abundant protein localized in synaptic vesicles that 
ameliorates neurodegeneration in cellular and animal models (Johnson et al., 2010). It 
contains a Dna-J domain and has been shown to interact with Hsc70 and to increase its 
ATPase activity (Braun et al., 1996). On the other hand, CSPα was shown to assemble into an 
enzymatically active ternary complex with Hsc70 and SGT (small glutamine-rich 
tetratricopeptide repeat domain protein) with a likely regulatory function in secretory 
vesicles (Tobaben et al., 2001). CSPα has also been reported to interact with other 
chaperones, including Hsp90 (Sakisaka et al., 2002), Hip, Hop (Rosales-Hernandez et al., 
2009), and Hsp40 (Gibbs et al., 2009). 
CSPα dysfunction has been implicated in various pathologies, including memory 
impairment, type-2 diabetes, cystic fibrosis, and HD (reviewed in (Johnson et al., 2010)). A 
few years ago, a link between CSPα and PD was also established (Chandra et al., 2005). The 
results of this study, performed using a transgenic mouse model, indicate that αSyn 
cooperates with CSPα in preventing neurodegeneration (Chandra et al., 2005). In a recent 
study (Sharma et al., 2011), the CSPα-Hsc70-SGT complex was found to bind to monomeric 
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SNAP-25, a pre-synaptic SNARE protein, and prevent its aggregation, thus promoting the 
formation of the SNARE complex involved in neuronal synapse. Interestingly, another 
recent study using a transgenic mouse model of αSyn aggregation with associated 
neurodegeneration, has shown that SNAP-25 is redistributed within synaptic terminals and 
the protein was found to colocalize with αSyn within intraneuronal aggregates (Garcia-
Reitbock et al., 2010).  These data raise the question whether aggregating αSyn might 
actually be sequestering CSPα involved in the CSPα-Hsc70-SGT complex, analogously to 
what was observed for aggregating huntingtin (Miller et al., 2003), and therefore enabling 
the aggregation of SNAP-25 in a PD scenario. 
2.4.2 The unfolded protein response (UPR) in PD 
The unfolded protein response (UPR) is a mechanism activated within the cell when the 
endoplasmic reticulum (ER) function is impaired and, as a result, unfolded proteins 
accumulate in the ER lumen (a process called ‘ER stress’). The ER-resident Hsp70 family 
member GRP78 (HSPA5/BiP) recognizes and binds to such unfolded proteins, which causes 
the release of UPR-activating factors (Rutkowski & Kaufman, 2004). To restore ER function, 
the UPR reduces protein translation and enhances the folding and processing capacities 
within ER. However, if the stress overwhelms the cell restoring capacity, the UPR induces 
apoptosis (Paschen & Mengesdorf, 2005). A few years ago, a mutation in the parkin gene 
was found to be related to familiar PD due to the impairment of its ubiquitin ligase function 
which results in protein accumulation within the ER lumen and leads to ER stress and 
apoptosis (Imai et al., 2001). More recently, a strong correlation between UPR activation and 
PD pathogenesis in PD patients was established (Hoozemans et al., 2007), suggesting a 
functional connection between αSyn and ER stress. In addition, it was found that 
overexpression of (Wt) ǂSyn triggers UPR in yeast (Cooper et al., 2006). A recent study has 
shown that αSyn is also found aggregated and accumulated within the ER lumen and 
induces UPR by binding to GRP78/BiP in cells, which could lead to apoptosis (Bellucci et 
al., 2011). Clearly, supplementary investigations are needed to determine the exact role of 
the UPR in the pathophysiology of PD. 
2.4.3 Mitochondrial dysfunction in PD 
In both familial and sporadic forms of PD, several mitochondrial alterations and increase of 
oxidative species are well recorded (Jellinger, 2010). The important role of mitochondrial 
pathology in PD is reflected by the specific and selective loss of mitochondrial complex I 
activity in the SN of PD patients (Valente et al., 2004). Results from a study with neuronal 
cell cultures indicate that this impairment is dependent on αSyn mitochondrial import and 
accumulation (Devi et al., 2008). Interestingly, a recent proteomic study revealed that 
expression of mortalin (HSPA9/mtHSP70/GRP75), a mitochondrial stress protein and 
member of the Hsp70 chaperone family which binds to DJ-1 and αSyn (Jin et al., 2007), is 
significantly decreased in PD brains (De Mena et al., 2009; Jin et al., 2006) as well as in a 
cellular model of PD (Jin et al., 2006). Moreover, specific coding mutational variants of the 
mortalin gene have been recently discovered in a few PD patients (Burbulla et al., 2010; De 
Mena et al., 2009). Finally, differential levels of mitochondrial mortalin were measured in Wt 
and A53T cellular models of PD (Pennington et al., 2010), suggesting a possible involvement 
of αSyn aggregation in PD-related mitochondrial dysfunction (Xie et al., 2010). 
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3. The Hsp70 machinery members as biomarkers of PD 
A biomarker is a naturally occurring molecule, gene, or characteristic by which a particular 
medical condition, disease, etc. can be identified. Despite the current relevance of 
identifying a biomarker for early diagnosis of PD and/or to follow up its progression, up to 
date there is no reliable biomarker available (Morgan et al., 2010; Nyhlen et al., 2010). 
Therefore, certain key proteins that are thought to be tightly linked to PD pathogenesis or 
progression, such as the members of the Hsp70 machinery discussed above, which could 
manifest changes in their expression levels in body fluids cells or alter their presence in 
body fluids in a PD scenario, could represent potential markers of disease development or 
predisposition. 
Currently, it is well established the most promising biomarkers for PD in cerebrospinal 
fluidic (CSF) are αSyn, DJ-1, amyloid ǃ, and the tau protein. These are the principal 
targets in the Parkinson’s Progression Markers Initiative, a public-private, large-scale 
study project that aims to identify biological markers of disease progression 
(www.PPMI-info.org). DJ-1, which is the only chaperone to be included in this study, is a 
mitochondrial chaperone which has been one of the most studied proteins for its 
potential use as a PD biomarker. However, results published thus far from 
measurements of DJ-1 in CSF (Hong et al., 2010) and serum from PD patients (Hong et 
al., 2010; Shi et al., 2010; Waragai et al., 2007) are somewhat controversial or inconsistent, 
which could probably be explained by the high DJ-1 protein level present in blood cells 
(Shi et al., 2010). 
Currently, it is well established that certain proteins, including members of the Hsp70 
family such as Hsp701A and 1B, display perturbed expression levels in the SN of PD 
brains (Hauser et al., 2005); however, changes in tissue expression levels are in principle 
not useful for an application as biomarkers. Recently, a significant decrease in whole 
blood mRNA levels of St13/Hip co-chaperone was reported for early PD patients, but not 
for AD patients or healthy controls (Scherzer et al., 2007). However, a second group 
reported no significant differences in the expression pattern of ST13 in early-stage PD 
patients, as compared to controls (Shadrina et al., 2010). This discrepancy could be 
attributed, at least in part, to heterogeneity in the criteria of diagnosing and classifying the 
individuals into groups and to the difficulty in establishing the actual onset of the disease. 
Yet another study found differences in HSPA8 (Hsc70) and HIP2 expression levels 
between PD patients and controls (Grunblatt et al., 2010). Other members of the Hsp70 
machinery are known to change their expression patterns in PD patients compared to 
healthy controls (Hauser et al., 2005). Unfortunately, these changes appear not specific or 
sufficient to differentiate between PD and other related neurodegenerative disorders 
(Hauser et al., 2005). This is probably due to the fact that the Hsp70 system plays a central 
role in maintaining cell proteostasis, which is perturbed in a variety of neurodegenerative 
diseases. 
Considering that PD is a complex pathology that involves several systems such as the stress 
response, the UPS, the immune system, etc., a unique biomarker might not be enough as a 
tool for diagnosis or follow-up of disease progression. Instead, there is general consensus 
that the use of a set of distinct parameters, such as protein expression profiles, age, 
symptoms and others, would probably be the best approach (Fasano et al., 2008; Grunblatt 
et al., 2010; Scherzer et al., 2007).  
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4. The Hsp70 system as a therapeutic tool for PD 
As described in this chapter, in the last few years it has become evident that HSPs play an 
important role in the initiation and progression of PD and other neurodegenerative diseases. 
This cumulative evidence has prompted the development of therapeutic tools based on the 
Hsp70 machinery. Different strategies have been tested to manipulate Hsp70 as a 
therapeutic approximation for PD and related neurodegenerative diseases (reviewed in 
Kalia 2010). Three general approaches have been explored, namely, to increase the 
intracellular activity of Hsp70, to overexpress Hsp70 and/or other co-chaperones, and to 
deliver chaperones or regulatory factors using cell-penetrating peptides (CPPs). 
4.1 Increasing the intracellular activity of Hsp70 
Theoretically, it should be feasible to control the activity of the cellular chaperone machinery 
by using different types of drugs. The mechanism of most of such chemical compounds is 
based on activating HSF-1, a key transcriptional regulator of the heat shock response (HSR) 
that activates the gene expression of inducible HSPs. One way of activating HSF-1 is by 
inhibiting Hsp90 activity; as a result, HSF-1 becomes active and increases the expression of 
inducible chaperones like HSPA1A/Hsp72 and others. Geldanamycin (GA) and its 
derivative 17-allylamino-17-demethoxygeldanamycin (17-AAG) are antibiotics with high 
affinity for the ATPase domain of Hsp90, which blocks its interaction with HSF-1 and 
subsequently allows its activation (Waza et al., 2006; Zou et al., 1998). GA prevents αSyn-
induced dopaminergic cell loss in cell culture (McLean et al., 2004) and in animal models of 
PD (Auluck et al., 2005; Shen et al., 2005), while the less toxic 17-AAG has also proven to be 
neuroprotective in PD cellular models (Danzer et al., 2011; Riedel et al., 2010) and in two 
animal models of PD-related neurodegenerative diseases (Fujikake et al., 2008; Waza et al., 
2005). Even though 17-AAG is currently under phase-II clinical trials as an anti-tumour drug 
(Pacey et al., 2010; Richardson et al., 2010; Solit et al., 2008), its use in patients with 
neurodegenerative diseases could be hampered by its toxicity and unavailability for oral 
administration (Pacey et al., 2010). Another family of inhibitors of Hsp90 activity, is SNX-
2112 and its analogues, which are orally available and present improved blood brain barrier 
(BBB) permeability. In particular, SNX-0723 was shown to prevent αSyn oligomer formation 
and αSyn-induced toxicity in cell culture (Putcha et al., 2010), and preclinical studies for 
cancer therapy are proving their safety (Zhai et al., 2011), although similar studies in 
neurodegenerative animal models are still needed. 
Other drugs are able to activate HSF-1 without inhibiting Hsp90 activity, which could 
represent a less toxic approximation for neurodegenerative pathologies. Arimoclomol, for 
example, has already been tested in phase I- and IIa-clinical trials for treating ALS, and 
shown to be safe and tolerable (Cudkowicz et al., 2008; Phukan, 2010). Another example is 
HSF-1A (Neef et al., 2010), shown to upregulate Hsp70 expression and to reduce poly-Q-
citotoxicity in cell and fly models of poly-Q neurodegenerative disorders (Neef et al., 
2010). Celastrol, yet a similar drug, and some structural relatives, appear as promising 
drugs due to their rapid kinetics and low EC50 (Westerheide et al., 2004), although further 
studies are needed. 
Besides these approaches, HSF-1 co-inducers could represent more tolerable drugs for therapy. 
These are molecules that partially activate HSF-1, reducing its activation threshold and often 
working in conjunction with secondary stress signals to fully induce HSR. Non steroidal anti-
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inflammatory drugs (NSAIDs) are well known co-inducers of HSR. For example, Sodium 
salicylate and Indomethacin induce HSF-1 DNA binding and reduce the temperature required 
for triggering the HSR (Jurivich et al., 1995; Lee et al., 1995). The association of NSAIDs use 
with a lower risk of common neurodegenerative diseases such as AD and PD has been 
analysed in several studies (Etminan et al., 2008; Gagne & Power, 2010). According to one 
hypothesis, this negative correlation could be due to continuous up-regulation of HSR and 
consequently continued cytoprotection against neurodegenereration (Westerheide et al., 2004). 
4.2 Overexpression of Hsp70 and/or related co-chaperones 
In principle, it should be possible to design a gene therapy approach for the treatment of PD 
and other conformational neurodegenerative diseases based on HSPs, considering the 
substantial number of reports having characterized the molecular pathways by which 
Hsp70 acts in the context of disease. Intriguingly, even though overexpression of Hsp70 has 
been shown to be protective in animal models of PD (Dong et al., 2005; Jung et al., 2008), a 
recent study in mouse indicates otherwise (Shimshek et al.). Up to date, one phase-I study in 
PD patients using recombinant Adeno-Associated Virus (AAV) to deliver aromatic 
aminoacid decarboxylase enzyme into the putamen, supports the proof-of-principle for the 
use of gene therapy in PD (Christine et al., 2009). With this precedent, gene therapy could 
potentially be employed to overexpress other chaperones and co-chaperones that may 
improve Hsp70 function and its neuroprotective properties. Indeed, recombinant AAV has 
been already used to transduce Hsp104 (Vashist et al., 2010), a non-mammalian chaperone, 
in a rat model of PD and proven to be neuroprotective by disaggregating protein inclusions 
and synergizing with endogenous Hsp70 (Lo Bianco et al., 2008). 
Given that co-chaperone BAG-5 is known as a negative regulator of Hsp70, downregulation 
of its expression has been tested in a mouse model of PD. In this study, direct expression in 
the SN by recombinant AAV delivery of BAG-5(DARA), a BAG-5 mutant which inhibits 
wild-type BAG-5 activity, resulted in increased dopaminergic neuron survival (Kalia et al., 
2004). Another possible approach to increase Hsp70 function by using gene therapy 
techniques could be gene silencing by RNA interference to knockdown Hsp70 
downregulators. Although these techniques have not been extensively tested for 
neurodegenerative therapy, they remain a potentially useful tool (Manfredsson et al., 2006). 
4.3 Chaperones or regulatory factors delivery using CPPs 
Cell penetrating peptides (CPPs) are the most recent approximation that shows promise 
towards increasing Hsp70 activity within cells. These are peptide motifs that allow cell 
transduction of macromolecules including functional full-length proteins. The basic domain 
of the trans-activator of transcription (TAT) from HIV-1 is the best known among CPPs and 
it has been shown that fusion with TAT allows proteins to penetrate cell membranes of 
several cell types and even to cross the BBB (Fawell et al., 1994; Schwarze et al., 1999). In the 
last few years, TAT-Hsp70 transduction has been reported to be neuroprotective against 
different kinds of stress in cell models (Lai et al., 2005; Nagel et al., 2008) as well as in a 
MPTP mouse model of PD (Nagel et al., 2008). In addition, transduction of TAT-Hsp40 has 
also been shown to be cytoprotective against oxidative stress in cells (Kim et al., 2008). 
Finally, transduction of HSF-1(+)-TAT, an HSF-1 mutant fused to TAT, capable of activating 
HSR by itself by itself, was demonstrated to induce to induce Hsp70 expression and to 
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protect cells against heat stress in vitro (Hou & Zou, 2009). Although further investigation is 
needed, CPPs tagging could prove a powerful tool in therapy against neurodegenerative 
diseases by allowing the efficient transduction of cytoprotective proteins and factors. 
5. Conclusions 
There is strong experimental support to propose the Hsp70 chaperone system as a key 
player in pathogenesis and progression of PD. This central role seems to be especially linked 
to αSyn, although alternative connections between the Hsp70 machinery and different 
pathogenic mechanisms underlying PD might exist. Up to this point, there is substantial 
evidence supporting an active role of Hsp70 in well established PD-related processes. First, 
in the inhibition or modulation of αSyn aggregation pathway that results in the formation of 
LBs and the suppression of αSyn-mediated toxicity to cells that leads to neurodegeneration. 
Second, a prominent role in the control of the activity of the UPS machinery, the general 
protein degradation and disposal system in the cell. And third, a central role in CMA, which 
handles the lysosomal degradation of selected cytosolic proteins, including αSyn. In 
addition, emerging mechanisms for Hsp70 in relation to PD include its participation in the 
CSPα-Hsc70-SGT complex in the neuron, and the increasing attention paid to the UPR and 
mitochondrial dysfunction processes in PD, both of which rely on Hsp70. 
The accumulated studies thus far suggest that Hsp70 chaperone is a highly versatile protein 
whose anti-aggregation activity seems to involve different interactions and the formation of 
transient and highly dynamic complexes with various αSyn species, presumably early 
oligomers and probably monomers, along the aggregation pathway. This activity can be 
certainly modulated by the presence of nucleotides and by certain co-chaperones, in 
particular, Hip. Clearly, further in vitro and in cell studies with Hsp70 and co-chaperones, to 
better understand the full molecular mechanism of mammalian Hsp70 in managing αSyn 
aggregation, are needed. 
As a biomarker of PD, Hsp70 seems not to represent a good candidate itself, probably due to 
its central role in maintaining cellular proteostasis which is perturbed in several 
amyloidoses and related diseases. However, the Hsp70 co-chaperone Hip might represent a 
potentially useful biomarker for early diagnosis of PD, although more studies are needed in 
this direction. Given that PD is a complex disease, a ‘complex biomarker’ (i.e. composed of 
various markers) appears to be the only reliable option. Finally, the Hsp70 machinery can be 
indirectly enhanced by HSF-1 pharmacological activation, which represents one of the most 
promising therapeutic approaches for treating this complex and highly debilitating disease. 
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